NCT02573766
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
At risk: Primary completion moved 2 years later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 14 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2028
- Eligibility criteria expanded, about 15 words
- Study description expanded, about 9 words
- Study Identification, Study Status, Oversight, IPDSharingv19
- Notable Primary and study completion dates: Oct 1, 2024 to Oct 1, 2026v18
- Notable Primary and study completion dates pushed to Oct 1, 2024v13
- Minor Study completion date: Oct 2019 to Oct 2020v12
Show 8 earlier versionsHide 8 earlier versions
- Minor Study completion date: Oct 2020 to Oct 2019v11
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 99 to confirmed 91
- Start date: Oct 2015 to Oct 1, 2015
- Site details revised
- Minor Enrollment target: 100 to 99v9
- Minor Enrollment target: 90 to 100
- Study description shortened, about 66 words
- Minor Study completion date: Oct 2019 to Oct 2020v7
- Notable Eligibility criteria shortened, about 28 words
- Study completion date: Oct 2019
- Study description revised
- Minor Collaborators: 1 to 2v3
- Minor Study description expanded, about 62 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
Procedures: Neurofeedback Training, Electroencephalogram
Behavioral: Pain Scale, Questionnaires
Sites
1 site in 1 country
- University of Texas MD Anderson Cancer CenterHouston, Texas, United States